Abstract 37P
Background
Atypical Ductal Hyperplasia (ADH) is a pre-malignant high-risk breast lesion, with morphological features similar to that of ductal carcinoma in situ (DCIS). The WHO diagnosis of ADH is defined as cytonuclear and architectural atypia <2mm in size. The current standard management is surgical excision, due to its reported 10-30% risk of upgrade to breast cancer. However, an increasingly observed alternative management utilizes a conservative approach with annual radiological follow up, quoting lower upgrade risks of 3-5%. Indications for conservative follow-up include low-risk patients or intial biopsy with vacuum assistance. Our primary aim is to investigate the ADH upgrade risk in a Singapore cohort, with a secondary goal of comparing upgrade cancer rates in upfront surgical management versus upgrade rates on conservative surveillance, to discuss feasibility of adopting a primarily conservative approach for the population.
Methods
A retrospective study was performed of 221 patients diagnosed with ADH between January 2013 to June 2023 in a tertiary institute. Initial biopsy histology, management approach and patient outcomes were evaluated. Outcome was measured by upgrade to early breast cancer. Odds ratio & relative risk was used to adjust for demographics, risk profile and biopsy methods.
Results
221 patients were diagnosed with ADH on biopsy, of whom 8 opted for surveillance. There was an overall upgrade risk of 31.22%, with 75.36% of upgrade histology being DCIS. Of all upgrades, 97.10% were diagnosed on upfront surgical excision after a mean period of 39 days, while 2.9% were diagnosed after a period of conservative surveillance. Of the 8 patients opting for conservative management, 1 patient received repeat biopsy and another 2 patients received surgical excision after a mean period of 268 days.
Conclusions
Our findings of a 31% upgrade risk of ADH to early breast cancer, consistent with that of reported literature, still support the case for upfront surgical excision of ADH. We recommend upfront surgical excision of ADH once discovered on initial biopsy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract